What does Trevi Therapeutics, Inc. do?
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral…
What is Trevi Therapeutics, Inc.'s P/E and P/B ratio?
Trevi Therapeutics, Inc. has a P/E ratio of -36.0 and a P/B ratio of 5.59.
What is Trevi Therapeutics, Inc.'s debt-to-equity ratio?
Trevi Therapeutics, Inc. has a debt-to-equity ratio of 0.00.
How much does Trevi Therapeutics, Inc. owe compared with what it owns?
Trevi Therapeutics, Inc. owes $0.03 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Trevi Therapeutics, Inc.'s Positivity rank?
Trevi Therapeutics, Inc. is ranked #5,238 of 6,775 companies globally and #2,800 of 4,000 in United States on PositoAI, with a Positivity Score of 18,075.
Does Trevi Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Trevi Therapeutics, Inc..
Where can I read the latest news about Trevi Therapeutics, Inc.?
Recent headlines about Trevi Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Trevi Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Trevi Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.